MDWD - MediWound Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.0700
-0.0500 (-1.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.1200
Open4.1300
Bid3.9800 x 1800
Ask4.1300 x 900
Day's Range3.9800 - 4.2580
52 Week Range3.7600 - 7.3500
Volume17,131
Avg. Volume105,054
Market Cap110.618M
Beta (3Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateJul 28, 2017 - Jul 31, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of MDWD earnings conference call or presentation 21-May-19 12:30pm GMT

    Q1 2019 Mediwound Ltd Earnings Call

  • MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 days ago

    MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

    MediWound (MDWD) delivered earnings and revenue surprises of -7.14% and -23.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 days ago

    MediWound: 1Q Earnings Snapshot

    The Yavne, Israel-based company said it had a loss of 15 cents per share. The developer of treatments for burns and hard-to-heal wounds posted revenue of $461,000 in the period. The company's shares closed ...

  • GlobeNewswire2 days ago

    MediWound Reports First Quarter 2019 Financial Results

    Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel.

  • GlobeNewswire9 days ago

    MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first quarter ended March 31, 2019 at 8:30 am Eastern Time on Tuesday, May 21, 2019. Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. Eastern Time to discuss the financial results and to answer questions.

  • Vericel (VCEL) Q1 2019 Earnings Call Transcript
    Motley Fool16 days ago

    Vericel (VCEL) Q1 2019 Earnings Call Transcript

    VCEL earnings call for the period ending March 31, 2019.

  • GlobeNewswire17 days ago

    MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has entered into exclusive license and supply agreements with Vericel Corporation (VCEL) to commercialize NexoBrid® in North America (NA). NexoBrid is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns, which is approved in the European Union and other international markets. The pivotal U.S. phase 3 DETECT clinical study met its primary and all secondary endpoints, and the submission of the Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) is planned for the fourth quarter of 2019.

  • Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know
    Zacks21 days ago

    Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know

    MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MDWD earnings conference call or presentation 25-Mar-19 12:30pm GMT

    Q4 2018 Mediwound Ltd Earnings Call

  • GlobeNewswire2 months ago

    MediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”). The annual report on Form 20-F, which contains MediWound’s audited financial statements, can be accessed on the SEC’s website at http://www.sec.gov, as well as via the Company’s investor relations website at http://ir.mediwound.com/investor-relations. The Company will deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Jeremy Feffer, Managing Director, LifeSci Advisors, at jeremy@lifesciadvisors.com.

  • Associated Press2 months ago

    MediWound: 4Q Earnings Snapshot

    The Yavne, Israel-based company said it had profit of 39 cents per share. Losses, adjusted for non-recurring gains and to account for discontinued operations, were 6 cents per share. The results surpassed ...

  • GlobeNewswire2 months ago

    MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued.

  • GlobeNewswire2 months ago

    MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2018 at 8:30 am Eastern Time on Monday, March 25, 2019. Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. Eastern Time to discuss the financial results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-602-7189 (in the U.S.), 1809 315 362 (Israel), or 678-894-3057 (outside the U.S. & Israel) and entering passcode 2997019.

  • GlobeNewswire2 months ago

    MediWound Announces Executive Leadership Changes

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Chief Executive Officer, Gal Cohen, has decided to step down after serving as the Company’s CEO for more than 12 years. Mr. Cohen will end his term by the end of May 2019 and during this period, continue to support the Company’s transition and ongoing strategic process. Sharon Malka, the Company’s Chief Financial Officer and Chief Operations Officer, will be appointed CEO, and Stephen T. Wills, the Company’s Chairman of the Board of Directors, will serve as Active Chairman.

  • Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline
    Zacks2 months ago

    Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline

    MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Do Institutions Own MediWound Ltd. (NASDAQ:MDWD) Shares?
    Simply Wall St.3 months ago

    Do Institutions Own MediWound Ltd. (NASDAQ:MDWD) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Looking to Set the Pace on Tuesday (1/22/19)

    With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. Premier Health Group (OTC:PHGRF) (CSE:PHGI), MediWound Ltd (MDWD), Neovasc Inc (NVCN), and Teladoc Health Inc (TDOC) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) has enjoyed impressive gains over the last three weeks as the company has taken strides to make key investments in the cannabis industry, allowing for the integration of new approaches to treatment options for their patients.

  • GlobeNewswire4 months ago

    MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has met its primary and all secondary endpoints in its pivotal U.S. Phase 3 clinical study (DETECT) with NexoBrid to treat patients with deep partial thickness (DPT) and full thickness (FT) thermal burns intended for submission for Biological License Application (BLA) from U.S. Food and Drug Administration (FDA). “We are thrilled to announce these robust positive results across all endpoints, which corroborate our previous positive EU Phase 3 clinical study results and clearly demonstrate the significant beneficial impact NexoBrid has on patients’ lives,” said Gal Cohen, President and Chief Executive Officer of MediWound.

  • ACCESSWIRE4 months ago

    MediWound’s Late Stage Clinical Products Review, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / January7, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean and Russian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of MDWD earnings conference call or presentation 13-Nov-18 1:30pm GMT

    Q3 2018 Mediwound Ltd Earnings Call

  • Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
    Zacks5 months ago

    Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

    Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

  • MediWound Ltd (NASDAQ:MDWD): Time For A Financial Health Check
    Simply Wall St.6 months ago

    MediWound Ltd (NASDAQ:MDWD): Time For A Financial Health Check

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like MediWound Ltd (NASDAQ:MDWD), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...

  • MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
    Zacks6 months ago

    MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates

    MediWound (MDWD) delivered earnings and revenue surprises of 42.11% and -17.97%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    MediWound: 3Q Earnings Snapshot

    On a per-share basis, the Yavne, Israel-based company said it had a loss of 11 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire6 months ago

    MediWound Reports Third Quarter 2018 Financial Results

    Awarded additional BARDA contract valued up to $43 Million for the development of NexoBrid® for sulfur mustard injuries Conference call begins today at 8:30 a.m. Eastern Time.